Drug intelligence / Profile preview

keynatinib

Development stage: Phase 2
Lead developer: Medolution
Modality: Small Molecules
Administration: Oral

Overview

Keynatinib is an investigational small molecule drug developed by Medolution for the treatment of various cancers, including non-small cell lung cancer (NSCLC), brain metastases, and relapsed/refractory B-cell lymphomas. It acts as a Bruton's tyrosine kinase (BTK) inhibitor and also has activity as an epidermal growth factor receptor (EGFR) inhibitor. Keynatinib is being evaluated in clinical trials for its efficacy, safety, pharmacokinetics, and ability to penetrate the blood-brain barrier. The drug is administered orally[6][10].

Other names: keynatinib

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on keynatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on keynatinib.

Explore the full profile